Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06317103
Other study ID # WAY-CTP-WME01-MSM
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 22, 2023
Est. completion date August 22, 2023

Study information

Verified date March 2024
Source WAYCEN Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this clinical trial is to prove that the prediction capability of 'WAYMED endo' is superior to that of the endoscopists in classifying EGC based on the depth of invasion categories in gastro-endoscopic images. The computer-aided detection·diagnosis software is an Artificial Intelligence (AI) software used to assist medical specialists in diagnostic decisions by automatically classifying EGC based on the depth of invasion categories in gastro-endoscopic images and displaying the results and possibilities on the User Interface (UI).


Description:

This clinical trial aims to evaluate the sensitivity and specificity of 'WAYMED endo' compared to that of endoscopists in classifying EGC based on the depth of invasion categories in gastro-endoscopic images. It is designed as a retrospective, single-center, double-arm, double-blind (endoscopist, investigational medical device applicator), controlled, and pivotal trial. Medical data collected retrospectively from subjects who underwent Esophagogastroduodenoscopy (EGD) and biopsy are screened. As a result of screening, medical data that meet all inclusion/exclusion criteria are enrolled and assigned to the trial and control groups. In the trial group, the investigational medical device is applied to the images, while the endoscopists interpret the images in the control group. The Reference Standard Establishment Committee records the reference standard results as either "Mucosa (mucosal invasion)" or "Submucosa (submucosal invasion)", based on the depth of invasion of the lesion, and marks the detected lesion area with an oval on the image. The reference standard results are blinded, so they cannot be disclosed to the endoscopists or the investigational medical device applicator. The primary endpoint includes the sensitivity (%) and specificity (%) of "WAYMED endo" and the endoscopists in classifying EGC based on the depth of invasion categories ("Mucosa" or "Submucosa") as confirmed by the reference standard. The secondary endpoint includes the accuracy (%) of "WAYMED endo" and the endoscopists in accurately classifying all early gastric cancer images as either "Mucosa" or "Submucosa", based on the depth of invasion categories as confirmed through pathological examination.


Recruitment information / eligibility

Status Completed
Enrollment 653
Est. completion date August 22, 2023
Est. primary completion date August 22, 2023
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. Patients aged 19 years or older who underwent EGD 2. Confirmed the presence of gastric cancer through the Electronic Medical Record (EMR), including reports of EGD or pathology 1. M ("Mucosa (mucosal invasion)"): Medical data of early gastric cancer patients with confirmed "Mucosa" for the depth of invasion category in the EMR. 2. SM ("Submucosa (submucosal invasion)"): Medical data of early gastric cancer patients with confirmed "Submucosa" for the depth of invasion category in the EMR. Exclusion Criteria: 1. Absence of pathological results for the lesion 2. History of gastrectomy 3. Judged as inappropriate for inclusion by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Device:
WADYMED endo
Classification of the gastro-endoscopic images as "Mucosa" or "Submucosa" by WADYMED endo (Gastric cancer image, computer aided detection/diagnosis software)
Other:
Control group (the endoscopists)
Interpretation of the gastro-endoscopic images as "Mucosa" or "Submucosa" by the endoscopists

Locations

Country Name City State
Korea, Republic of Yonsei University Gangnam Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
WAYCEN Inc

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Sensitivity in classifying early gastric cancer (EGC) based on the depth of invasion (%) The probability of being classified as "Mucosa (mucosal invasion)", based on the depth of invasion categories for early gastric cancer, among gastro-endoscopic images confirmed as "Mucosa" through the results of pathologic examination. 3 months
Primary Clinical Specificity in classifying early gastric cancer (EGC) based on the depth of invasion (%) The probability of being classified as "Submucosa (submucosal invasion)", based on the depth of invasion categories for early gastric cancer, among gastro-endoscopic images confirmed as "Submucosa" through the results of pathologic examination. 3 months
Secondary Accuracy in classifying the depth of invasion categories ("Mucosa" or "Submucosa") for early gastric cancer (%) The probability of accurately classifying all early gastric cancer images as either "Mucosa" or "Submucosa", based on the depth of invasion categories confirmed through pathological examination. 3 months
See also
  Status Clinical Trial Phase
Terminated NCT04977401 - EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection N/A
Not yet recruiting NCT04083573 - Comparison of Diagnostic Performance of Medical Monitor and Medical Augmented Reality Glasses in Endoscopy: Observation Study
Completed NCT02504164 - Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection N/A
Recruiting NCT01774266 - Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer N/A
Completed NCT01435525 - Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation N/A
Completed NCT01921283 - Monitored Anesthesia Care With Propofol Plus Remifentanil During Endoscopic Submucosal Dissection: Evaluation of Bispectral Index Monitoring N/A
Completed NCT01364324 - Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
Recruiting NCT03837301 - Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2) Phase 2
Recruiting NCT05269056 - Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics
Not yet recruiting NCT03632746 - Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients
Completed NCT01938326 - Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) Versus Totally Laparoscopic Distal Gastrectomy (TLDG) N/A
Recruiting NCT04602689 - Fibrin Glue After ESD for High Risk Patients of Bleeding N/A
Recruiting NCT05291728 - Screening for Early Gastric Cancer in Shaanxi Province
Not yet recruiting NCT06152783 - Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study
Completed NCT02189226 - Usefulness of Probe-based Confocal Laser Endo-microscopy in Delineation of Margin of Early Gastric Cancer for Endoscopic Submucosal Dissection N/A
Completed NCT04602299 - Setting the Shortest Examination Time of Gastroscopy to Improve the Detection Rate of Upper Gastrointestinal Tumors N/A
Completed NCT02562976 - OLGA Stage is More Appropriate in Predicting Early Gastric Cancer N/A
Recruiting NCT01132469 - Efficacy and Safety Study of Endoscopic Submucosal Dissection for Early Gastric Cancer N/A
Completed NCT03136354 - Prospective Randomized Trial Comparing Endoscopic Submucosal Dissection Against Laparoscopic Assisted Gastrectomy for Treatment of Early Gastric Cancer N/A
Completed NCT02216110 - Endoscopic Submucosal Dissection Versus Gastrectomy N/A